Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ups And Downs For Lab Tests In Senate Health Reform Bill

This article was originally published in The Gray Sheet

Executive Summary

Senate health care reform 1legislation up for floor debate this week contains both positives and negatives for makers of in vitro diagnostics and for testing labs, but would reduce expected Medicare payment cuts in the sector compared to the package approved by the Senate Finance Committee last month

You may also be interested in...



CMS In Brief

Cardiac stenting conviction, settlement

CMS In Brief

Cardiac stenting conviction, settlement

Senate Chooses Baucus Approach To Comp. Effectiveness, With Tweaks

The Senate health reform 1bill up for floor debate this week essentially retains the industry-supported Baucus/Conrad approach to a national comparative effectiveness research infrastructure, but includes some subtle changes of note

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel